HT patch causes fewer breast changes than pill

Article

Transdermal hormone therapy causes fewer and less severe changes in breast density and less breast tenderness than oral HT, according to a study involving 202 postmenopausal women sponsored by Novartis.

Transdermal hormone therapy causes fewer and less severe changes in breast density and less breast tenderness than oral HT, according to a study involving 202 postmenopausal women sponsored by Novartis.

The two agents compared in the study were Estalis/Combipatch (Novartis, Basel, Switzerland) and Kliogest (Schering AG, Berlin, Germany).

The researchers found that mean breast density with the transdermal product was 38% versus 47% with the oral product (P<0.0001). Of the women using transdermal HT, 39% experienced no change in breast density versus 16% of the women using oral HT. Only 4% using the transdermal form had more than a 25% increase in density versus 16% of the women using the oral form. And 36% of the women in the transdermal group reported breast tenderness during the 1-year study versus 58% of the oral group (P=0.0002).

Newsletter

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

Recent Videos
Thomas McElrath, MD, PhD, highlights limitations of current preeclampsia guidelines | Image Credit: physiciandirectory.brighamandwomens.org.
Jane Varney, MD, discusses how a low FODMAP diet mediates gut symptoms caused by endometriosis | Image Credit: lens.monash.edu.
Ousseny Zerbo, PhD, highlights benefits of influenza vaccination during pregnancy | Image Credit: divisionofresearch.kaiserpermanente.org.
Michael Ussher, PhD, highlights the benefits of vaping over smoking in pregnancy | Image Credit: sgul.ac.uk.
Neal Barnard, MD, FACC, highlights AMA's new breast cancer prevention guidelines | Image Credit: pcrm.org.
Related Content
© 2025 MJH Life Sciences

All rights reserved.